Issue: March 2013
Perspective from Jack M. Bert, MD
Perspective from Michael X. Repka, MD
February 04, 2013
2 min read
Save

CMS issues final rule on Physician Payment Sunshine Act

Issue: March 2013
Perspective from Jack M. Bert, MD
Perspective from Michael X. Repka, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CMS recently announced in a press release its final rule on the National Physician Payment Transparency Program: Open Payments, also known as the Sunshine Act, aimed to increase transparency among physicians, drug and device manufacturers and health care providers.

As part of the Affordable Care Act, the rule calls for manufacturers of drugs, devices, biologics and medical supplies reimbursed by Medicare, Medicaid or Children’s Health Insurance Program to disclose payments made to doctors and teaching hospitals to CMS. According to the release, these manufacturers and group purchasing organizations must also report physician ownership and investments in these enterprises. This data will be publicly available on a CMS website by September 30, 2014, and entities required to report information under the rule will be able to review and correct reported data before it is released to the public. Collection of this information will begin August 1 of this year, according to the release.

 

Jeremy Lazarus

“You should know when your doctor has a financial relationship with the companies that manufacture or supply the medicines or medical devices you may need,” Peter Budetti, MD, CMS deputy administrator for Program Integrity, stated in the press release. “Disclosure of these relationships allows patients to have more informed discussions with their doctors.”

AMA President Jeremy Lazarus, MD, stated that the AMA will carefully review the new rule.

“Physicians’ relationships with the pharmaceutical industry should be transparent and focused on benefits to patients,” Lazarus stated in an AMA press release. “Our feedback during this rulemaking process was aimed at ensuring the new registry will provide a meaningful picture of physician-industry interactions and give physicians an easy way to correct any inaccuracies. As the rule is implemented, we will work to make sure physicians have up-to-date information about the new reporting process.”

Click to view a chart from Arnold & Porter LLC that provides more detailed information on key aspects of the rule, including comparisons between the proposed and final rules and brief summaries of CMS’ stated rationale for its decisions.

Reference:

https://www.federalregister.gov/public-inspection